A review on newly approved PARP inhibitors: Talazoparib and Olaparib

A review on newly approved PARP inhibitors: Talazoparib and Olaparib

This project report is submitted in partial fulfillment of the requirements for the degree of Bachelor of Pharmacy, 2024.

Dettagli Bibliografici
Autore principale: Karim, Azrin
Altri autori: Islam, Farzana
Natura: Project report
Lingua:English
Pubblicazione: Brac University 2024
Soggetti:
PARP inhibitors
Olaparib
Talazoparib
DNA damage repair
DDR signaling pathway
Homologous recombination repair
Prostate cancer
Ovarian cancer
Metastatic breast cancer
BRCA mutations
Cancer > Treatment > Genetic aspects.
DNA repair.
NAD-ADP-ribosyltransferase > Inhibitors > Therapeutic use.
Antineoplastic agents.
Accesso online:http://hdl.handle.net/10361/24372

Accesso online

http://hdl.handle.net/10361/24372

Documenti analoghi